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Objectives The goal of this study was to evaluate the prospective association of fetuin-A levels with cardiovascular disease
(CVD) mortality.
Background Fetuin-A is a circulating inhibitor of calcium deposition in the vasculature and of insulin action in muscle and fat,
and may be involved in the pathogenesis of CVD.
Methods This is a population-based prospective study of 633 men and 1,025 women (median age  73 years) who had
fetuin-A levels and CVD risk factors evaluated in 1992 to 1996 and were followed for vital status through 2010.
Results Plasma fetuin-A (g/l  SD) was highest in women using oral estrogens (0.55  0.12), intermediate for women
not using oral estrogens (0.51  0.10), and lowest for men (0.50  0.10), p  0.001. Lower fetuin-A levels
were associated with older age, but with lower levels of other CVD risk factors including adiposity, blood pres-
sure, lipids, triglycerides, and insulin resistance (all p  0.01). During the median 12-year follow-up, 273 deaths
were attributed to CVD. The association of fetuin-A with CVD mortality differed by diabetes status (p for interac-
tion  0.003). Adjusting for age, sex, oral estrogens, and lifestyle, the hazard ratio for CVD mortality comparing the
lowest fetuin-A quartile with all higher values was 1.76 (95% confidence interval [CI]: 1.34 to 2.31; p  0.001) for
participants without diabetes and 0.43 (95% CI: 0.19 to 0.98; p  0.046) for participants with diabetes.
Conclusions Low fetuin-A levels predicted greater risk for CVD mortality in older adults without diabetes, but were associated
with reduced risk of CVD death in those with diabetes. Fetuin-A may provide novel insight into mechanisms lead-
ing to CVD death in those with versus without diabetes. (J Am Coll Cardiol 2012;59:1688–96) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.038Fetuin-A is a multifunctional liver-derived protein found in
high concentrations in human serum (1). Two of the
primary physiological functions of fetuin-A may be critically
important to cardiovascular health. First, fetuin-A acts as an
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30, 2011, accepted January 6, 2012.inhibitor of calcification by increasing the blood solubility of
calcium and phosphorus, and preventing spontaneous min-
eral precipitation in the vasculature (2,3). In end-stage renal
disease populations, lower plasma fetuin-A levels are asso-
ciated with greater prevalence and severity of vascular
calcification (4,5) and increased risk of cardiovascular dis-
ease (CVD) events and mortality (5–8), independent of
traditional CVD and kidney disease risk factors. Recent
evidence suggests that fetuin-A may also inhibit vascular
calcification in individuals with normal kidney function. We
and others demonstrated that lower fetuin-A levels are
independently correlated with coronary artery calcification
in older adults with normal kidney function and no known
CVD (9) and with cardiac valvular calcification in a cohort
with normal kidney function and prevalent CVD (10,11).
Fetuin-A also regulates insulin signaling. Only 2 proteins
are known to bind directly to the extracellular domain of
the insulin receptor—insulin and fetuin-A. Experimental
evidence indicates that fetuin-A binding inhibits the
insulin receptor tyrosine kinase (12) and induces insulin
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studies, higher fetuin-A levels are associated with insulin
resistance among individuals without diabetes (14–16) and
predict incident type 2 diabetes mellitus, independent of
other markers of insulin resistance (17,18).
These dual physiological roles of fetuin-A are evident in
fetuin-A knockout mice who are characterized by ectopic
calcification, but also display greater insulin sensitivity and
resistance to weight gain compared with their wild-type
littermates (19–21). Thus, fetuin-A sufficiency may be
necessary to prevent vascular calcification, but fetuin-A
excess may lead to insulin resistance and metabolic
dysregulation. In this study, we examined the prospective
association of plasma fetuin-A levels with CVD mortality
among community-dwelling older adults from the Rancho
Bernardo study. On the basis of the existing literature, we
hypothesized that lower fetuin-A levels would be associated
with increased CVD mortality risk in individuals without
diabetes mellitus, and hypothesized no association of
fetuin-A with CVD death in diabetics due to competing
influences of insulin resistance and calcification in this
subset.
Methods
Study population. Between 1972 and 1974, community-
dwelling residents living in Rancho Bernardo, California,
aged 30 to 79 years were invited to participate in a study of
heart disease risk factors, and 82% (n  5,052) enrolled.
Nearly all were middle to upper-middle class, and relatively
well educated. Since then, sequential study visits have been
conducted at approximately 4-year intervals. The present
analysis included individuals who participated in the 1992 to
1996 clinic visit. The study was approved by the Institu-
tional Review Board of the University of California San
Diego; all participants gave written informed consent.
Eligibility criteria for the present analysis included: 1) age
50 years or older when evaluated at the 1992 to 1996 visit;
2) availability of stored sera; 3) post-menopausal status for
women; and 4) follow-up for vital status. Of the 1,781
participants who attended the 1992 to 1996 clinic visit, 49
were excluded for age 50 years, 6 women for pre-
menopausal status, 39 for insufficient stored plasma for
fetuin-A determination, and 8 for no follow-up after their
1992 to 1996 visit. The final sample consisted of 663 men
and 1,025 women.
During the 1992 to 1996 visit, information regarding
medical history, medication use, physical activity, alcohol
consumption, and current smoking was obtained using
standard questionnaires. Current medication use was vali-
dated by examination of pills and prescriptions brought to
the clinic for that purpose, and participants were asked to
rate their overall health on a 5-point scale (excellent, very
good, good, fair, or poor).
Clinical measurements. Height, weight, and waist and hip
girth were measured in the clinic with participants wearing tlight clothing and no shoes.
Body mass index (BMI) (kg/m2)
and waist-to-hip ratio were used
as estimates of overall and central
adiposity, respectively. Blood
pressures were measured twice in
seated resting subjects using the
Hypertension Detection and
Follow-Up Program protocol
(22); the mean of the 2 measures
was used in analyses.
Blood samples were obtained
by venipuncture between 0730 h
and 1100 h after a requested
12-h fast; serum and plasma were
separated and frozen at 70°C.
Fetuin-A levels were measured
in duplicate in 2010 on EDTA
plasma samples using a human enzyme-linked immunoad-
sorbent assay kit (Epitope Diagnostics, San Diego, Califor-
nia). This assay uses a 2-site “sandwich” technique with
polyclonal antibodies that bind different epitopes of human
fetuin-A. Intra-assay and interassay coefficients of variation
were 2.4% to 4.7% and 9.5% to 9.9%, respectively, for the
set of assays used for the present sample. Plasma total and
high-density lipoprotein (HDL) cholesterol and triglycer-
ides were measured in a Centers for Disease Control
Certified Lipid Research Clinic laboratory using established
methods (23). Low-density lipoprotein (LDL) cholesterol
was calculated using the Friedewald equation. Serum creat-
inine was measured using the Jaffe reaction; liver enzymes by
spectrophotometry; and serum phosphorus and calcium by a
standard clinical automated analyzer.
Prevalent conditions and mortality assessment. Prevalent
CVD was defined as physician-diagnosed myocardial in-
farction, coronary artery revascularization, congestive heart
failure, stroke or transient ischemic attack, carotid surgery,
peripheral arterial surgery, or physician-diagnosed intermit-
tent claudication. Validation of self-reported heart attack
(by chest pain, enzyme elevation, and electrocardiography)
was achieved for 72% of a subset for whom hospital records
could be obtained. Diabetes was defined by physician
diagnosis, fasting plasma glucose 126 mg/dl, 2-h post-
challenge glucose 200 mg/dl, or use of diabetes medica-
ions. The metabolic syndrome was defined according to the
002 Adult Treatment Panel III criteria (24). Hypertension
as defined as blood pressure 140/90 mm Hg or use of
ntihypertensive medication. Estimated glomerular filtra-
ion rate (eGFR) was calculated by the MDRD (Modifica-
ion of Diet in Renal Disease study) equation (25); partic-
pants with eGFR 60 ml/min/1.73 m2 were classified as
aving moderate chronic kidney disease (26). Homeosta-
is model assessment for insulin resistance (HOMA-IR)
as used to estimate insulin resistance (27). Comorbidi-
Abbreviations
and Acronyms
BMI  body mass index
CI  confidence interval
CVD  cardiovascular
disease
eGFR  estimated
glomerular filtration rate
HDL  high-density
lipoprotein
HOMA-IR  homeostasis
model assessment for
insulin resistance
HR  hazard ratio
LDL  low-density
lipoproteinies recorded included thyroid, liver, kidney, and heart
py; HDL
l
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tis, hip fracture, and hypertension.
Participants were followed through 2010, with 98%
ascertainment of vital status. Death certificates were classi-
fied for underlying cause of death by a certified nosologist
using the International Classification of Diseases, Ninth
Revision. CVD deaths included codes 401 to 448.
Statistical analysis. On the basis of a priori hypotheses of
nonlinear associations, we evaluated quartiles of fetuin-A.
Preliminary analysis demonstrated substantial differences in
fetuin-A levels by sex and by use of oral estrogens in
women; therefore, participants were categorized into sex-
and oral estrogen–specific quartiles of fetuin-A levels.
Trends in baseline characteristics by fetuin-A quartiles were
evaluated using analysis of variance with linear trend for
continuous variables and Cochran-Armitage test for trend
for nominal variables. HDL cholesterol and triglyceride
levels were not normally distributed and were log-
transformed for analyses; reported values are geometric
means and interquartile ranges. Skew was 0.09 and 0.26,
and kurtosis 2.67 and 3.29, after log-transformation for
Baseline Characteristics of the Study Population by Sex and Oral ETable 1 Baseline Characteristics of the Study Population by Se
Total
(N  1,688)
Q1
(n  42
Fetuin, g/l†
Men (n  663) 0.50 (0.10) 0.26, 0.4
Women—no oral ET (n  623) 0.51 (0.10) 0.25, 0.4
Women—using oral ET (n  402) 0.55 (0.12) 0.22, 0.4
Demographic and anthropomorphic factors
Age, yrs 72.2 (10.5) 75 (10)
Body mass index, kg/m2 25.4 (4.0) 24.5 (3.7)
Waist circumference, cm 85.3 (12.8) 83.5 (12.3
Waist-to-hip ratio 0.84 (0.09) 0.84 (0.09
CVD risk factors
Systolic blood pressure, mm Hg 136.8 (22.1) 137 (22)
Diastolic blood pressure, mm Hg 75.7 (9.5) 75 (10)
Total cholesterol, mg/dl 209.6 (36.6) 202 (35)
LDL cholesterol, mg/dl 126.9 (32.5) 121 (32)
HDL cholesterol, mg/dl‡ 55.7 (45, 69) 57 (46, 7
Triglycerides, mg/dl‡ 105.6 (74, 148) 92 (66, 1
Fasting plasma glucose, mg/dl 98.7 (23.0) 95.9 (17.3
HOMA-IR 2.7 (2.3) 2.4 (2.3)
eGFR, ml/min/1.73 m2 67.5 (16.1) 67 (17)
Health status markers
Number of comorbidities 1.5 (1.2) 1.6 (1.2)
Number of medications 1.2 (0.6) 1.2 (0.6)
Fair/poor self-assessed health, % 9.1 11.4
Lifestyle parameters, %
Current smoker, yes 6.9 7.6
Exercise, 3 times/week 70.8 69.3
Daily alcohol (vs. less or none) 33.3 40.5
*Test for linear trend; †mean (SD) for total and minimum, maximum for quartiles; ‡geometric m
CVD cardiovascular disease; eGFR estimated glomerular filtration rate; ET estrogen thera
ipoprotein.HDL cholesterol and triglycerides, respectively.Single-predictor associations between the variables listed
in Table 1 and fetuin-A levels were determined by linear
regression analysis. Multivariable regression analysis was
used to determine which covariates were independently
associated with fetuin-A levels.
The association between fetuin-A and CVD mortality
was determined using Cox proportional hazards regressions;
model assumptions were tested by applying the time-
dependent covariate test (28), by Schoenfeld residual visu-
alizations (29), and by visualization of log-log survival plots
and Kaplan-Meier versus Cox estimated survivor functions
(30). All models presented met the proportional hazards
assumption. Three separate regression models were as-
sessed: the first adjusted for age, sex and use of oral
estrogens; the second added adjustment for lifestyle charac-
teristics including physical activity (3 times per week,
yes/no), alcohol use (1 drinks/day vs. less or none), and
current smoking habit (yes/no); and the third added adjust-
ment for traditional CVD risk factors (BMI, waist-to-hip
ratio, systolic blood pressure, triglycerides, LDL cholesterol,
fasting plasma glucose, HOMA-IR, and eGFR). There was
en–Specific Quartile of Fetuin-Ad Oral Estrogen–Specific Quartile of Fetuin-A
Fetuin-A Quartile
p Trend*
Q2
(n  422)
Q3
(n  423)
Q4
(n  422)
0.44, 0.50 0.50, 0.56 0.56, 1.24 —
0.44, 0.51 0.51, 0.57 0.57, 0.86 —
0.47, 0.54 0.54, 0.63 0.63, 1.04 —
72 (10) 71 (11) 70 (10) 0.001
25.4 (4.2) 25.7 (3.9) 26.1 (4.1) 0.001
85.0 (12.9) 85.4 (12.4) 87.5 (13.4) 0.001
0.84 (0.09) 0.84 (0.09) 0.85 (0.10) 0.03
136 (22) 136 (23) 138 (22) 0.60
75 (9) 76 (9) 77 (9) 0.001
209 (37) 212.2 (35) 216 (38) 0.001
127 (33) 129 (31) 131 (33) 0.001
57 (47, 70) 55 (45, 68) 53 (42, 66) 0.001
100 (68, 142) 112 (79, 159) 124 (85, 184) 0.001
99.2 (20.8) 99.7 (26.7) 100.2 (25.9) 0.007
2.5 (1.9) 2.7 (2.3) 3.2 (2.6) 0.001
68 (15) 68 (17) 68 (15) 0.47
1.5 (1.2) 1.3 (1.1) 1.5 (1.2) 0.02
1.2 (0.5) 1.2 (0.6) 1.2 (0.5) 0.85
9.7 6.6 8.8 0.08
8.3 5.0 6.7 0.27
73.2 71.6 69.0 0.82
34.7 32.1 25.8 0.001
artile 1 [Q1], quartile 3 [Q3]).
 high-density lipoprotein; HOMA-IR homeostasis model insulin resistance; LDL low-densitystrogx an
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Cox models were performed to test the influence of specific
comorbidities and of a set of health status markers. Biolog-
ically plausible effect modifiers were tested by interaction
terms on a multiplicative scale.
All p values presented are 2-tailed; p  0.05 was
onsidered statistically significant for all analyses, including
nteraction terms. Data were analyzed using STATA
v11.1, Stata Corp., College Station, Texas) and SPSS
v155, SPSS Inc., Chicago, Illinois).
esults
aseline characteristics. Baseline characteristics are pre-
ented in Table 1. The mean age of the 1,688 participants
as 72 years (range: 50 to 98); 61% (n  1,025) were
emale, of whom 402 (39%) reported current use of oral
strogens. Fetuin-A levels (median, interquartile range in
rams/liter) were highest in women using oral estrogens
0.54, 0.47 to 0.63), intermediate for women not using oral
strogens (0.51, 0.44 to 0.57), and lowest for men (0.50,
.44 to 0.56) (p  0.001 for all). Use of non-oral estrogens
n  37 women) did not influence fetuin-A levels (data not
hown); these women were included in the no oral estrogen
roup.
etuin covariates. The linear associations of individual
ariables with fetuin-A levels are shown in Table 2. Oral
strogen therapy, female sex, and triglycerides showed the
trongest individual positive associations with fetuin-A
Beta-Coefficients for Individual and MultivariablTable 2 Beta-Coefficients for Individual and
Independent Variable* -Coeffic
Oral estrogen therapy 0.04
Demographics
Sex (1  male) 0.02
Age (10.5 yrs) 0.02
Anthropomorphics
Body mass index (4.0 kg/m2) 0.01
Waist-to-hip ratio (0.09) 0.00
CVD risk factors
Systolic blood pressure (22.1 mm Hg) 0.00
Diastolic blood pressure (9.5 mm Hg) 0.00
HDL cholesterol (17.4 mg/dl) 0.00
LDL cholesterol (23.5 mg/dl) 0.00
Triglycerides (77.0 mg/dl) 0.02
Fasting plasma glucose (23.0 mg/dl) 0.00
HOMA-IR (2.3) 0.00
eGFR (16.1 ml/min/1.73 m2) 0.00
Lifestyle parameters
Daily alcohol (vs. less or none) 0.02
Current smoker (yes vs. no) 0.00
Exercise (3 times/week) 0.00
*Continuous explanatory variables were standardized prior to analysis,
betas presented. Adjusted R2  0.14.
Abbreviations as in Table 1.evels with age and daily alcohol consumption showing the ptrongest negative associations. In multivariate analyses, oral
strogen therapy, systolic blood pressure, LDL cholesterol,
nd triglycerides were independently associated with higher
evels of fetuin-A, whereas older age and daily alcohol
onsumption associated with lower fetuin-A levels (adjusted
2  0.14).
Overall, 18% of participants met criteria for the metabolic
yndrome, 14% had diabetes, and 20% had prevalent CVD.
he prevalence of the metabolic syndrome and diabetes
ncreased in a stepwise fashion across fetuin-A quartiles,
hereas the prevalence of CVD decreased as fetuin-A levels
ncreased (Fig. 1) (all p  0.001 for linear trend).
VD mortality. During the 16-year follow-up (median 12
ears), 273 deaths were attributed to CVD (153 women,
20 men). Results of Cox proportional hazards models for
VD mortality by fetuin-A quartile are presented in Table 3. The
ge-, sex-, and oral estrogen therapy–adjusted hazard ratio
HR) for the lowest quartile of fetuin-A versus the
ighest was 1.30 (95% confidence interval [CI]: 0.93 to
.78, p  0.12) for CVD mortality. HRs for the 2nd and
rd quartiles were not significantly different than 1.0,
uggesting a low threshold (a significant test for quadratic
rend [p  0.018] supported the nonlinear association of
etuin quartiles with CVD risk). Further adjustment for
ifestyle factors (Model 2) had minimal influence on the
ow fetuin-A association. Adding adjustment for tradi-
ional CVD risk factors increased the HR for the lowest
ersus the highest quartile to 1.42 (95% CI: 1.01 to 1.99,
ressions on Fetuin-A Levelsivariable Regressions on Fetuin-A Levels
idual Multivariable†
p Value -Coefficient p Value
0.001 0.0331 0.001
0.001
0.001 0.0227 0.001
0.001
0.03
0.24 0.0095 0.003
0.01
0.23
0.001 0.0064 0.012
0.001 0.0192 0.001
0.27
0.001
0.43
0.001 0.0203 0.001
0.47
0.41
in parentheses are 1 SD. †Model included all variables, only significante RegMult
Indiv
ient
91
74
32
12
56
02
69
35
98
73
28
89
20
61
70
46
values 0.041).
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Next, we examined whether the association of low fetuin-A
with CVD mortality differed across strata of selected risk
factors comparing low fetuin-A levels (quartile 1) with all
higher (quartiles 2 to 4) and adjusting for age, sex, oral
estrogen therapy, alcohol intake, regular exercise, and cur-
rent smoking as appropriate (Table 4). There was no
statistical evidence of effect modification by age, sex, over-
weight (BMI25 kg/m2 vs. lower), daily alcohol consump-
ion, HOMA-IR, hypertension, hypercholesterolemia, hy-
ertriglyceridemia, metabolic syndrome, prevalent CVD, or
y death in the first 10 years of follow-up versus after 10
ears (p interactions all 0.29). Use of oral estrogens did
ot modify the association of low fetuin-A with CVD
ortality in women (p interaction  0.63) (data not
hown).
A strong interaction was observed for diabetes (p inter-
ction  0.003), such that low fetuin-A levels were associ-
ted with 76% higher risk of CVD death in individuals
ithout diabetes (p  0.001), but with 57% lower risk of
VD death in those with diabetes (p  0.046) (Fig. 2).
hese differences persisted after adjustment for additional
VD risk factors including BMI, waist-to-hip ratio, tri-
lycerides, LDL cholesterol, systolic blood pressure, fasting
lasma glucose, HOMA-IR, and eGFR. In this multiply
djusted model, the HR for CVD mortality for low
etuin-A levels versus higher was 1.90 (95% CI: 1.43 to
Figure 1 Prevalence of Metabolic Syndrome, Diabetes, and Pre
p 0.001 for linear trend for all. Lines within the bars indicate binomial exact con
Multivariable Cox Proportional Hazards Models for the AssociationTable 3 Multivariable Cox Proportional Hazards Models for the
Fetuin Quartile
(Range, g/l)
Mortality
Rate*
Model 1†
HR (95% CI) p Va
Q1 (0.220.47) 20 1.30 (0.93, 1.78) 0.1
Q2 (0.440.54) 15 0.89 (0.62, 1.28) 0.5
Q3 (0.500.63) 13 0.76 (0.52, 1.11) 0.1
Q4 (0.561.24) 16 1.00 (Ref)
*Indirect standardization for age, deaths per 100. †Model 1, adjusted for age, sex, and oral estro
2  body mass index, waist-to-hip ratio, triglycerides, LDL cholesterol, systolic blood pressure, fasting glu
CI  confidence interval; HR  hazards ratio; Q  quartile; Ref  reference category; other abbreviati.50; p 0.001) for nondiabetic patients and 0.48 (95% CI:
.20 to 1.14; p  0.097) for those with diabetes.
econdary analyses by diabetes status. The influence of
nown and unknown comorbidities and overall health status
n the diabetes-specific association of low fetuin-A with
VD mortality was examined in secondary analyses com-
aring low fetuin-A levels to all higher; adjusted for age,
ex, oral estrogen therapy, alcohol intake, regular exercise,
nd current smoking (Table 5). In sequential analyses,
dding adjustment for metabolic syndrome, prevalent CVD,
r a set of health status markers had minimal effect on low
etuin-A risk estimates in either the diabetes or no diabetes
roup. Excluding participants with the metabolic syndrome
r prevalent CVD modestly attenuated the low fetuin-A
ssociation in the diabetic group, but had minimal influence
n risk estimates for the no diabetes group. Excluding CVD
eaths that occurred within the first 2 years of follow-up did
ot alter results.
In the diabetes group, adding adjustment for liver func-
ion markers to the base model strengthened the association
f low fetuin-A with CVD mortality, whereas adjusting for
erum phosphorus and calcium reduced it; neither adjust-
ent influenced results for the nondiabetic group (Table 5).
djusting for HOMA-IR, or sequential adjustment for the
ost commonly used medications (aspirin, calcium supple-
ents, and antihypertensive agents used by 34%, 34%, and
0% of participants, respectively) (data not shown) also
t CVD by Fetuin-A Quartile
e intervals.
artile of Fetuin-A With CVD Mortalityciation of Quartile of Fetuin-A With CVD Mortality
Model 2‡ Model 3§
HR (95% CI) p Value HR (95% CI) p Value
1.30 (0.94, 1.80) 0.12 1.41 (1.01, 1.99) 0.043
0.90 (0.62, 1.29) 0.56 0.93 (0.65, 1.36) 0.70
0.78 (0.53, 1.14) 0.20 0.72 (0.48, 1.06) 0.13
1.00 (Ref) 1.00 (Ref)
rapy. ‡Model 2, model 1  alcohol use, current smoking, and regular exercise. §Model 3, modelvalen
fidencof QuAsso
lue
2
4
6
gen the
cose, eGFR, and HOMA-IR.
ons as in Table 1.
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for effect modification within the nondiabetic group, the
association of low fetuin-A with increased risk of CVD
death was not modified by HOMA-IR, by overweight
(BMI 25 kg/m2), or by obesity (BMI 30 kg/m2) (p
alues for interaction 0.30).
iscussion
his study evaluated the prospective association of plasma
etuin-A levels with CVD mortality in a large population of
lder, community-dwelling men and women. We observed
striking difference in the association of fetuin-A with
VD mortality risk by diabetes status. Low fetuin-A levels
ere associated with 76% higher risk of CVD death in
Multivariable Hazard Ratios for CVD Mortality b(Q artile 1) Versus Higher (Quartiles 2 to 4) StrTable 4 Multivariabl Hazard Ratios for CVD(Quartile 1) Versus Higher (Quartile
Group Events/N Person-Y
All 273/1,679 17,41
Sex
Male 120/659 6,59
Female 153/1,020 10,82
Age
72 yrs 27/776 9,45
72 yrs 246/903 7,95
Overweight
BMI 25 kg/m2 152/845 8,45
BMI 25 kg/m2 116/822 8,88
HOMA-IR
2.2 (median) 113/820 8,57
2.2 157/851 8,77
Daily alcohol drinker
No 183/1,120 11,59
Yes 90/559 5,82
Metabolic syndrome
No 218/1,378 14,39
Yes 55/301 3,02
Diabetes
No 221/1,443 15,18
Yes 53/236 2,23
High blood pressure
No 49/535 6,07
Yes 224/1,144 11,34
High triglycerides
150 mg/dl 210/1,266 13,03
150 mg/dl 63/411 4,36
High cholesterol
200 mg/dl 126/679 6,73
200 mg/dl 147/999 10,67
Prevalent CVD
No 168/1,339 14,62
Yes 105/340 2,78
Time to CVD death
After 10 yrs 82/1,108 10,38
First 10 yrs 191/571 7,03
*Adjusted for age, sex, oral estrogen therapy, alcohol use, current sm
BMI  body mass index; other abbreviations as in Tables 1 and 3.ndividuals without diabetes, but with 57% lower risk of lVD mortality in those with diabetes. Both associations
ere statistically significant, and both were independent of
raditional CVD risk factors, insulin resistance, and mea-
ures of liver and kidney function. These findings are
onsistent with the hypothesis that fetuin-A protects
gainst vascular calcification, but promotes insulin resistance
nd metabolic dysregulation, and suggest that the balance
etween these 2 functions may depend on the metabolic
ilieu or prior disease processes.
The association of low fetuin-A with increased CVD risk
n individuals without diabetes is somewhat paradoxical
iven that low fetuin-A is also associated with beneficial
evels of most traditional CVD risk factors including lower
lood pressure, better lipids, lower adiposity, and reduced
Fetuin-Ad by Potential Moderatorstality by Low Fetuin-A
o 4) Stratified by Potential Moderators
HR (95% CI)*
p Value for
interaction
1.46 (1.14–1.87) —
1.27 (0.87–1.85) 0.29
1.68 (1.21–2.34) †
0.88 (0.33–2.36) 0.32
1.54 (1.19–2.00) ‡
1.52 (1.10–2.12) § 0.62
1.29 (0.86–1.93)
1.41 (0.96–2.06) 0.93
1.57 (1.12–2.19) ‡
1.45 (1.07–1.98) § 0.85
1.54 (1.01–2.36) §
1.48 (1.13–1.95) ‡ 0.88
2.09 (1.05–4.18) §
1.76 (1.34–2.31) † 0.003
0.43 (0.19–0.98) §
0.95 (0.52–1.74) 0.24
1.63 (1.24–2.15) *
1.49 (1.13–1.98) ‡ 0.93
1.62 (0.83–3.16)
1.57 (1.09–2.27) § 0.46
1.35 (0.95–1.92)
1.56 (1.13–2.14) ‡ 0.35
1.23 (0.82–1.85)
1.29 (0.81–2.06) 0.90
1.64 (1.22–2.23) ‡
and regular exercise. †p  0.001; ‡p  0.01; §p  0.05.y LowatifieMor
s 2 t
ears
7
0
6
0
7
5
9
7
8
5
2
1
6
6
1
1
6
4
0
0
3
9
8
5
2ikelihood of metabolic syndrome. Only older age and a
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fetuin-A, and in general, adjusting for these, as well as the
other CVD risk factors, strengthened the risk estimate for
fatal CVD among nondiabetic individuals with low
fetuin-A. Thus, mechanisms other than conventional
pathogenic pathways are likely to be involved in the biology
underlying the low fetuin-A association. Circulating
fetuin-A is a well-described inhibitor of vascular calcifica-
tion in patients with end-stage renal disease (4,5), an
association that has been extended to the general population
(10,11). We recently demonstrated that low fetuin-A levels
were also associated with coronary artery calcification in the
Rancho Bernardo participants (9). Whether vascular calci-
fication accounts for all, or most, of the CVD risk associated
Figure 2
Survival Plots Showing the
Differential Association of Low Fetuin-A
With CVD Mortality by Diabetes Status
Adjusted hazards ratios  1.76 (95% confidence interval [CI]: 1.34, 2.31,
p  0.001) for participants without diabetes (n  1,443) (A) and 0.43 (95%
CI: 0.19, 0.98, p  0.046) for those with diabetes (n  236) (B). Models are
adjusted for age, sex, oral estrogen therapy, current smoking, alcohol use,
and regular exercise.with low fetuin-A should be evaluated in future studies ofpopulations with baseline ectopic calcification measure-
ments and long-term follow-up.
Few prior studies have examined the association of
fetuin-A with CVD events in the general population, and
existing data are mixed. In a case-cohort study nested within
the EPIC-Potsdam study (European Prospective Investiga-
tion into Cancer and Nutrition–Potsdam study), high
plasma fetuin-A levels were associated with greater risk of
incident myocardial infarction and ischemic stroke (31);
results that are opposite in direction to our findings in
nondiabetic individuals and to observations in patients with
end-stage renal disease. Age differences may be important.
Our participants were 20 years older on average than the
EPIC-Potsdam cohort, and were probably more likely to have
prevalent arterial calcification at baseline than the EPIC-
Potsdam participants. If the link between low fetuin-A and
CVD events is mediated through accelerated arterial calcifica-
tion, then this difference may have made an association of low
fetuin-A with CVD risk more likely among our older nondi-
abetic participants. It is also possible that fetuin-A associations
with incident CVD events in a younger population (EPIC-
Potsdam) differs from that with fatal CVD events in an older
population (Rancho Bernardo).
In contrast to the nondiabetic group, low fetuin-A was
associated with significantly lower, not higher, risk of CVD
death in Rancho Bernardo participants with diabetes. In our
previous investigation in the Heart and Soul Study (a cohort
of 1,024 individuals, all of whom had prevalent CVD and a
spectrum of kidney function similar to that in the Rancho
Bernardo study), low fetuin-A levels were associated with
aortic stenosis among individuals without diabetes, whereas
no association was observed in those with diabetes (10).
This finding, as well as the dual actions of fetuin-A, led us
to the a priori hypothesis that the relationship of fetuin-A
with other measures of vascular calcification and CVD
would also differ by diabetes status. The present study
extends the link between low fetuin-A levels and vascular
disease to a prospective association with CVD mortality in
community-dwelling adults, and demonstrates that this
association is not dependent on pre-existing CVD. Impor-
tantly, we confirmed the observation that diabetes modifies
the fetuin-A association, using a distinct but related out-
come and in a different population. Diabetes was the only 1
of several potential effect modifiers that was statistically
significant, and the significance of the interaction was
strong (p  0.003). This new evidence supports the repro-
ducibility of our original findings and may lead to important
new insights with respect to fetuin-A biology.
Effect modification by diabetes was also examined in the
EPIC-Potsdam study, and none was found; however, dia-
betes cases were identified by self-report and examination of
medical records, and did not include fasting and post-
challenge glucose measurements as in the present study,
thus undiagnosed cases might have been missed. Most other
studies of fetuin-A and CVD have been in kidney disease
populations, and almost all have identified increased risk of
3 for d
e; othe
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viduals with low fetuin-A levels (4–8). One notable excep-
tion is a study reporting a direct correlation of fetuin-A
levels with the extent of coronary artery calcification among
diabetic patients in the pre-dialysis stages of chronic kidney
disease (32). This result is consonant with our finding of a
protective association of low fetuin-A with CVD mortality
among diabetic individuals and may be related to the role of
fetuin-A in mediating insulin resistance. Fetuin-A inhibits
the insulin receptor tyrosine kinase, preventing insulin-
mediated autophosphorylation of the insulin receptor (12)
and inducing insulin resistance (13). Fetuin-A knockout
mice demonstrate improved insulin sensitivity and resis-
tance to weight gain and fat accumulation when fed a
high-fat diet (19), and intraperitoneal delivery of fetuin-A
to wild-type mice acutely induces peripheral insulin resis-
tance (33). Thus, low fetuin-A may slow the development
or severity of insulin resistance and its consequences in
diabetic individuals.
We observed a direct association between plasma
fetuin-A and HOMA-IR, triglyceride levels, LDL choles-
terol, measures of adiposity, and diabetes prevalence; all of
which are consistent with a possible pathogenic role for
fetuin-A in exacerbating the insulin resistance and the
proatherogenic milieu associated with type 2 diabetes mel-
litus. This possibility is supported by prior studies by our
group and others showing that higher plasma fetuin-A
levels both predict incident diabetes and characterize those
with established diabetes (17,18). Low fetuin-A in individ-
uals with diabetes may represent a successful adaptive
response that reduces CVD risk in a subgroup of diabetes
patients. Many of the diabetic participants in the present
study were captured only by high fasting or post-challenge
glucose, and may therefore have been cases earlier in the
Multivariable Hazard Ratios for CVD Mortality bFetu n-A (Quartile 1) Versus Higher (Qu rtilesAdj sting for, or Excluding, P tential Cov r ates
Table 5
Multivariable Hazard R tios for CVD
Fetuin-A (Quartile 1) Versus Highe
Adjusting for, or Excluding, Potenti
No Diabete
HR (95% C
Events/N 220/1,450
Base model* 1.76 (1.34–2.
Base model* plus
Liver function (AST, ALT, albumin) 1.79 (1.36–2.
Serum phosphorus, calcium 1.80 (1.37–2.
Insulin resistance (HOMA) 1.78 (1.36–2.
Metabolic syndrome 1.83 (1.39–2.
Prevalent CVD 1.69 (1.29–2.
Health status markers† 1.72 (1.31–2.
Base model* excluding
Metabolic syndrome‡ 1.66 (1.25–2.
Prevalent CVD§ 1.80 (1.28–2.
CVD death within 2 yrs 1.66 (1.24–2.
*Base model adjusted for age, sex, oral ET, alcohol use, current smok
comorbidities, self-assessed health. ‡Events/N  191/1,267 for no
30/169 for diabetes. Events/N  196/1,425 for no diabetes, 47/22
ALT  alanine aminotransferase; AST  aspartate aminotransferasdisease course with a lower prevalence of vascular disease.Whether fetuin-A’s role in the pathogenesis of diabetic
CVD depends on the stage and severity of disease should be
addressed in future studies.
Strengths of this study are its prospective design, the
relatively large sample size, inclusion of both sexes, and the
availability of a wide spectrum of potential confounding
variables.
Study limitations. Associations were based on fetuin-A
values measured at a single time point; nonetheless, we
identified a strong signal for CVD mortality that was robust
to statistical adjustment for multiple covariates. Almost half
of the diabetes cases were identified based on fasting or
post-challenge glucose levels, not on physician diagnosis,
thus information on diabetes severity or duration was not
available. Participants were predominantly Caucasian and
middle to upper middle class. This limits generalizability,
but is a strength to the extent that confounding by ethnicity,
socioeconomic status, and access to health care is mini-
mized. Finally, the majority of participants were elderly men
and women, and our results may not generalize to younger
adults.
Conclusions
In summary, in community-dwelling individuals, low
plasma fetuin-A levels are independently associated with
increased risk of CVD mortality among men and women
without diabetes, but with reduced risk of CVD death in
those with diabetes. These results suggest the relationship of
fetuin-A to cardiovascular health is more complex than
previously thought. Future studies, with larger populations,
are required to determine whether measurement of plasma
fetuin-A will be useful as a CVD risk stratification tool and
whether prediction criteria will differ for those with and
4)Effect Modifierstality by Low
artiles 2 to 4)
variates and Effect Modifiers
p Value
Diabetes
HR (95% CI) p Value
53/238
0.001 0.43 (0.19–0.98) 0.046
0.001 0.36 (0.15–0.85) 0.020
0.001 0.52 (0.22–1.22) 0.132
0.001 0.43 (0.18–0.99) 0.048
0.001 0.43 (0.18–0.99) 0.047
0.001 0.49 (0.21–1.12) 0.089
0.001 0.48 (0.21–1.12) 0.090
0.001 0.49 (0.16–1.57) 0.23
0.001 0.58 (0.18–1.89) 0.37
0.001 0.43 (0.17–1.05) 0.06
ular exercise. †Health status markers: number medications, number
es, 27/117 for diabetes. §Events/N  138/1,175 for no diabetes,
iabetes.
r abbreviations as in Tables 1 and 3.y Low2 toandMor
r (Qu
al Co
s
I)
31)
36)
36)
34)
40)
22)
26)
22)
54)
21)
ing, reg
diabetwithout diabetes.
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